Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Active Biotech AB ( (SE:ACTI) ) has issued an update.
Active Biotech AB has updated its share capital structure following the completion of a rights issue, resulting in a total of 2,636,067,170 shares and votes outstanding as of the last trading day of the month. The expanded share base reflects the company’s ongoing financing efforts to support clinical development across its portfolio of immunomodulatory therapies for cancer and inflammatory eye diseases, and may influence ownership dynamics and liquidity for existing and new shareholders.
The most recent analyst rating on (SE:ACTI) stock is a Hold with a SEK0.04 price target. To see the full list of analyst forecasts on Active Biotech AB stock, see the SE:ACTI Stock Forecast page.
More about Active Biotech AB
Active Biotech AB is a Stockholm-listed biotechnology company developing first-in-class immunomodulatory treatments targeting oncology and immunology indications with high unmet medical need and commercial potential. Its pipeline comprises three main projects: tasquinimod for hematological cancers, with current focus on myelofibrosis and completed Phase Ib/IIa work in multiple myeloma; laquinimod for inflammatory eye disorders such as non-infectious uveitis, supported by a completed Phase I topical eye study ahead of planned Phase II with a partner; and naptumomab, a partnered targeted anti-cancer immunotherapy in Phase Ib/II trials for advanced solid tumors.
YTD Price Performance: -10.87%
Average Trading Volume: 9,428,790
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK106.8M
See more insights into ACTI stock on TipRanks’ Stock Analysis page.